Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Qualigen Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CARLSBAD, CA, JULY 28, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ:QLGN) ("QUALIGEN" OR THE "COMPANY"), A LIFE SCIENCES COMPANY FOCUSED ON DEVELOPING PLATFORM TREATMENTS FOR ADULT AND PEDIATRIC CANCERS WITH THE POTENTIAL FOR ORPHAN DRUG DESIGNATIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO DEFINITIVE SECURITIES PURCHASE AGREEMENTS WITH SEVERAL INSTITUTIONAL AND ACCREDITED INVESTORS FOR THE SALE OF ITS SERIES A-3 PREFERRED STOCK. THE PRIVATE PLACEMENT CLOSED ON JULY 28, 2025. THE COMPANY ISSUED AND SOLD AN AGGREGATE OF 4,500 SHARES OF SERIES A-3 PREFERRED STOCK, WITH A STATED VALUE OF $1,000 PER SHARE, FOR AGGREGATE GROSS PROCEEDS OF $4.5 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES. THE SERIES A-3 PREFERRED STOCK IS INITIALLY CONVERTIBLE INTO AN AGGREGATE OF 1,607,143 SHARES OF COMMON STOCK OF THE COMPANY AT A CONVERSION PRICE OF $2.80 PER SHARE, SUBJECT TO ADJUSTMENT IN ACCORDANCE WITH THE TERMS OF THE SERIES A-3 PREFERRED STOCK CERTIFICATE OF DESIGNATION.

QUALIGEN THERAPEUTICS ANNOUNCES $4.5 MILLION PRIVATE PLACEMENT OF SERIES A-3 CONVERTIBLE PREFERRED STOCK

CARLSBAD, CALIF., JULY 16, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY OR QUALIGEN) IS ANNOUNCING AN UPDATE ON PATENTS GRANTED IN THE FIRST SIX MONTHS OF 2025. THE PATENT IS TITLED SUBSTITUED NAPHTHALENE DIIMIDES AND THEIR USE. THE PATENT IS FOR THE DRUG, WHICH WAS DEVELOPED BY PROFESSOR STEPHEN NEIDLE AND HIS TEAM AT THE UNIVERSITY COLLEGE OF LONDON, AND IS LICENSED BY QUALIGEN THERAPEUTICS, QN-302. THESE PATENTS COVER THE PRODUCT AND THEIR METHODS OF MANUFACTURING.

QUALIGEN GRANTED NEW PATENTS COVERING 25 COUNTRIES

CARLSBAD, CALIF., MAY 19, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) ANNOUNCED TODAY THAT IT RECEIVED AN EXPECTED DEFICIENCY NOTIFICATION LETTER FROM THE LISTING QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC ("NASDAQ") ON MAY 19, 2025 (THE "NOTICE"). THE NOTICE INDICATED THAT THE NASDAQ HEARINGS PANEL (THE PANEL) WILL CONSIDER THE COMPANY'S FAILURE TO TIMELY FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2025 AS AN ADDITIONAL BASIS FOR DELISTING THE COMPANY'S SECURITIES FROM THE NASDAQ STOCK MARKET.

QUALIGEN THERAPEUTICS, INC. RECEIVES EXPECTED NOTIFICATION OF DEFICIENCY FROM NASDAQ RELATED TO DELAYED FILING OF QUARTERLY REPORT ON FORM 10-Q

CARLSBAD, CALIF., MAY 01, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) ANNOUNCED TODAY THAT IT RECEIVED AN EXPECTED DEFICIENCY NOTIFICATION LETTER FROM THE LISTING QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC (NASDAQ) ON APRIL 24, 2025 (THE "NOTICE"). THE NOTICE INDICATED THAT THE COMPANY WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C) (THE LISTING RULE) AS A RESULT OF ITS FAILURE TO TIMELY FILE ITS ANNUAL REPORT ON FORM 10-K FOR THE ANNUAL PERIOD ENDED DECEMBER 31, 2024 (THE 2024 FORM 10-K), AS DESCRIBED MORE FULLY IN THE COMPANY'S FORM 12B-25 NOTIFICATION OF LATE FILING (THE FORM 12B-25) FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") ON APRIL 1, 2025. THE LISTING RULE REQUIRES NASDAQ-LISTED COMPANIES TO TIMELY FILE ALL REQUIRED PERIODIC REPORTS WITH THE SEC.

QUALIGEN THERAPEUTICS, INC. RECEIVES NOTIFICATION OF DEFICIENCY FROM NASDAQ RELATED TO DELAYED FILING OF ANNUAL REPORT ON FORM 10-K

NEW YORK, NOV. 25, 2024 (GLOBE NEWSWIRE) -- UNIVEST SECURITIES, LLC (UNIVEST), A MEMBER OF FINRA AND SIPC, AND A FULL-SERVICE INVESTMENT BANK AND SECURITIES BROKER-DEALER FIRM BASED IN NEW YORK, TODAY ANNOUNCED THE CLOSING OF PRIVATE PLACEMENT OF 5,100 SERIES A-2 PREFERRED SHARES, WITH A STATED VALUE OF US$1,000 PER SHARE, FOR ITS CLIENT QUALIGEN THERAPEUTICS, INC. (NASDAQ:QLGN) (QUALIGEN OR THE COMPANY), A LIFE SCIENCE COMPANY FOCUSED ON DEVELOPING PLATFORM TREATMENTS FOR ADULT AND PEDIATRIC CANCERS, WITH THE POTENTIAL FOR ORPHAN DRUG DESIGNATIONS.

UNIVEST SECURITIES, LLC ANNOUNCES SUCCESSFUL CLOSING OF $5.1 MILLION PRIVATE PLACEMENT FOR QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN)

CARLSBAD, CALIF., NOV. 01, 2024 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) ANNOUNCED TODAY THAT IT WILL IMPLEMENT A 1-FOR-50 REVERSE STOCK SPLIT OF THE ISSUED SHARES OF ITS COMMON STOCK (THE "REVERSE STOCK SPLIT"), EFFECTIVE AT12:01 A.M. EASTERN TIMEONNOVEMBER 5, 2024. THE COMPANY'S COMMON STOCK IS EXPECTED TO BEGIN TRADING ON A SPLIT-ADJUSTED BASIS WHEN THE MARKET OPENS ONTUESDAY, NOVEMBER 5, 2024, AND WILL CONTINUE TO TRADE ON THE NASDAQ CAPITAL MARKET UNDER THE SYMBOL "QLGN." THE NEW CUSIP NUMBER FOR THE COMMON STOCK WILL BE74754R 301.

SHARES EXPECTED TO BEGIN TRADING ON SPLIT-ADJUSTED BASIS ONNOVEMBER 5, 2024

CARLSBAD, CALIF., SEPT. 26, 2024 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) ANNOUNCED ON SEPTEMBER 23, 2024, MR. MICHAEL POIRIER, NOTIFIED THE BOARD OF DIRECTORS OF THE COMPANY (THE BOARD") OF HIS INTENTION TO RESIGN AS CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF THE COMPANY, EFFECTIVE IMMEDIATELY. ON THE SAME DATE, MR. CHRISTOPHER LOTZ, CHIEF FINANCIAL OFFICE ALSO TENDERED HIS RESIGNATION FROM THE COMPANY, EFFECTIVE IMMEDIATELY. BOTH RESIGNATIONS WERE ATTRIBUTED TO DISAGREEMENTS WITH THE COMPANY REGARDING ITS FUTURE DIRECTION AND STRATEGIC INITIATIVES.

QUALIGEN THERAPEUTICS, INC. ANNOUNCES MANAGEMENT CHANGES.

CARLSBAD, CALIF., SEPT. 20, 2024 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) TODAY ANNOUNCED THAT ON SEPTEMBER 11, 2024, THE COMPANY RECEIVED A NOTICE FROM NASDAQ INDICATING THAT THE NASDAQ HEARINGS PANEL (PANEL) HAS GRANTED AN EXTENSION FOR THE CONTINUED LISTING OF THE COMPANY, SUBJECT TO THE COMPANY EVIDENCING COMPLIANCE WITH ALL APPLICABLE CRITERIA FOR CONTINUED LISTING ON THE NASDAQ CAPITAL MARKET BY NOVEMBER 19, 2024. THE COMPANY IS DILIGENTLY WORKING TO FULFILL THE REQUIREMENTS SET FORTH BY THE PANEL TO ENSURE THE COMPANY'S CONTINUED LISTING ON NASDAQ.

QUALIGEN THERAPEUTICS, INC. RECEIVED EXTENSION FROM NASDAQ HEARINGS PANEL

NEW YORK, SEPT. 06, 2024 (GLOBE NEWSWIRE) -- UNIVEST SECURITIES, LLC (UNIVEST), A MEMBER OF FINRA AND SIPC, AND A FULL-SERVICE INVESTMENT BANK AND SECURITIES BROKER-DEALER FIRM BASED IN NEW YORK, TODAY ANNOUNCED THE CLOSING OF REGISTERED DIRECT OFFERING (THE OFFERING) OF (I) 14,724,058 SHARES OF COMMON STOCK PRICED AT $0.130 PER SHARE, WITH PRE-FUNDED WARRANTS EXERCISABLE FOR 11,972,754 SHARES WITH RESPECT TO THE REGISTERED DIRECT OFFERING FOR ITS CLIENT QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY), A CLINICAL-STAGE THERAPEUTICS COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR ADULT AND PEDIATRIC CANCER.

UNIVEST SECURITIES, LLC ANNOUNCES CLOSING OF $3.46 MILLION REGISTERED DIRECT OFFERING FOR ITS CLIENT QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN)

CARLSBAD, CALIF., SEPT. 06, 2024 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF 14,724,058 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE (EACH A SHARE, AND COLLECTIVELY, THE SHARES) AT PUBLIC OFFERING PRICE OF $0.13 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE UP TO 11,972,754 SHARES AT A PRICE OF $0.129 PER SHARE WITH AN EXERCISE PRICE OF $0.001 PER SHARE (THE PRE-FUNDED WARRANTS).THE PRE-FUNDED WARRANTS ARE EXERCISABLE UPON ISSUANCE AND WILL REMAIN EXERCISABLE UNTIL ALL THE PRE-FUNDED WARRANTS ARE EXERCISED IN FULL.

Qualigen Therapeutics, Inc.

QLGN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Qualigen Therapeutics, Inc.

QLGN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

QLGN